1. Gass JD. Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol. 1967; 63(Suppl):1–139.
2. Daruich A, Matet A, Marchionno L, et al. Acute central serous abdominal: factors influencing episode duration. Retina. 2017; 37:1905–15.
3. Jalkh AE, Jabbour N, Avila MP, et al. Retinal pigment epithelium decompensation. I. Clinical features and natural course. Ophthalmology. 1984; 91:1544–8.
4. Ie D, Yannuzzi LA, Spaide RF, et al. Subretinal exudative deposits in central serous chorioretinopathy. Br J Ophthalmol. 1993; 77:349–53.
Article
5. Iida T, Yannuzzi LA, Spaide RF, et al. Cystoid macular abdominal in chronic central serous chorioretinopathy. Retina. 2003; 23:1–7. quiz 137–8.
6. Ficker L, Vafidis G, While A, Leaver P. abdominal follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol. 1988; 72:829–34.
7. Yeo YD, Kim JH, Kim YC, Kim KS. Photodynamic therapy and focal laser photocoagulation in chronic central serous choriretinopathy. J Korean Opthalmol Soc. 2016; 57:56–62.
8. Kim YS, Lee YH, Kim HS, et al. Comparison of therapeutic effect between half-energy photodynamic therapy and intravitreal abdominal injection in chronic central serous chorioretinopathy for 12 months. J Korean Opthalmol Soc. 2013; 54:1526–33.
9. Nicholson B, Noble J, Forooghian F, Meyerle C. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol. 2013; 58:103–26.
Article
10. Mirshahi M, Nicolas C, Mirshahi A, et al. The mineralocorticoid hormone receptor and action in the eye. Biochem Biophys Res Commun. 1996; 219:150–6.
Article
11. Zhao M, Célérier I, Bousquet E, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest. 2012; 122:2672–9.
Article
12. Ghadiali Q, Jung JJ, Yu S, et al. Central serous chorioretinopathy treated with mineralocorticoid antagonists: a one-year pilot study. Retina. 2016; 36:611–8.
13. Bousquet E, Beydoun T, Rothschild PR, et al. Spironolactone for nonresolving central serous chorioretinopathy: a randomized abdominalled crossover study. Retina. 2015; 35:2505–15.
14. Daruich A, Matet A, Dirani A, et al. Oral mineralocorticoid-receptor antagonists: real-life experience in clinical subtypes of nonresolving central serous chorioretinopathy with chronic epitheliopathy. Transl Vis Sci Technol. 2016; 5:2. eCollection 2016 Mar.
Article
15. Aronova A, Fahey TJ III, Zarnegar R. Management of abdominal in primary aldosteronism. World J Cardiol. 2014; 6:227–33.
16. Desai AS, Lewis EF, Li R, et al. Rationale and design of the abdominal of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of abdominal in patients with symptomatic heart failure and abdominal ejection fraction. Am Heart J. 2011; 162:966–72.e10.
17. de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of abdominal therapy in patients with true resistant hypertension. Hypertension. 2010; 55:147–52.
18. Herold TR, Rist K, Priglinger SG, et al. abdominal results and abdominal rates after spironolactone treatment in nonresolving abdominal serous abdominal (CSCR). Graefes Arch Clin Exp Ophthalmol. 2017; 255:221–9.
19. Falavarjani KG, Amirsardari A, Habibi A, et al. Visual and abdominal outcomes of spironolactone therapy in patients with chronic abdominal serous chorioretinopathy. J Ophthalmic Vis Res. 2017; 12:281–9.
20. Comez-Sanchez E, Gomez-Sanchez CE. The multifaceted abdominal receptor. Compr Physiol. 2014; 4:965–94.
21. Bousquet E, Beydoun T, Zhao M, et al. Mineralocorticoid receptor antagonism in the treatment of chronic central serous abdominal: a pilot study. Retina. 2013; 33:2096–102.
22. Sun X, Shuai Y, Fang W, et al. Spironolactone versus observation in the treatment of acute central serous chorioretinopathy. Br J Ophthalmol 2017 Oct 31. pii: bjophthalmol-2017–311096.doi:. DOI:
10.1136/bjophthalmol-2017-311096. [Epub ahead of print].
Article
23. Kapoor KG, Wagner AL. Mineralocorticoid antagonists in the treatment of central serous chorioretinopathy: a comparative analysis. Ophthalmic Res. 2016; 56:17–22.
Article